Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952699 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
A Phase 2 study of Narcolepsy Type 2, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT06952699 is a Phase 2 study of Narcolepsy Type 2 that is actively recruiting participants, run by Takeda. The registered enrollment target is 88 participants, below the 112-participant average among 4 other Narcolepsy Type 2 trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06952699, a Phase 2 study of Narcolepsy Type 2, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that. Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TAK-360
Study Locations (20)
California
- Takeda Site 14 - Redwood City
- Takeda Site 10 - Santa Ana
Florida
- Takeda Site 13 - Brandon
- Takeda Site 3 - Orlando
North Carolina
- Takeda Site 8 - Denver
- Takeda Site 6 - Huntersville
Other
- Takeda Site 15 - Paris
- Takeda Site 23 - Bologna
Colorado
- Takeda Site 1 - Colorado Springs
Missouri
- Takeda Site 4 - St Louis
Ohio
- Takeda Site 5 - Cincinnati
South Carolina
- Takeda Site 2 - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2026-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06952699
The ClinicalTrials.gov registry entry for NCT06952699 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 4 other Narcolepsy Type 2 trials with a reported enrollment target (21% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Narcolepsy Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06952699 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06952699 about?
NCT06952699 is a clinical study titled "A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)". Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night...
What is the current status of trial NCT06952699?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2025-05-06. Estimated completion is 2026-08-20.
What conditions does trial NCT06952699 study?
This clinical trial studies the following conditions: Narcolepsy Type 2.
What interventions are being tested in trial NCT06952699?
The interventions under investigation include: Placebo (OTHER), TAK-360 (DRUG).
Who is sponsoring clinical trial NCT06952699?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952699 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
RECRUITING · Phase 2
-
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
RECRUITING · Phase 2
-
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
RECRUITING · Phase 2
-
Narcolepsy Nightmare Study
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.